Medicus Pharma Charts Three-Year Path Amid Volatility, Bets on ADC and Rare Disease Assets

  • Medicus Pharma raised $90M since 2023 to fund clinical development, acquisitions, and operations.
  • CD228V ADC targets melanotransferrin (CD228) in melanoma and other solid tumors using Pfizer’s vedotin platform.
  • SkinJect Phase 2 study completed; registrational trial (SKNJCT-005) approved for Gorlin syndrome patients.
  • Teverelix acquired via Antev deal; optimized protocol submitted for advanced prostate cancer.

Medicus Pharma is pivoting from a single-asset company to a precision oncology portfolio, betting on ADCs and rare disease therapies. The shift mirrors broader biotech trends toward targeted therapies and capital-efficient development, but execution hinges on clinical data and strategic partnerships. With $90M raised since 2023, the company must now prove its assets can attract pharma partners amid market volatility.

Clinical Validation
Whether CD228V can demonstrate efficacy in melanoma and expand into other solid tumors.
Partnering Dynamics
The pace at which Medicus secures non-dilutive deals for SkinJect and Teverelix.
Capital Efficiency
How Medicus balances spending on multiple assets amid stock volatility.